Log in with your email address username.


[Correspondence] Risk of stent thrombosis with bioresorbable vascular scaffolds – Authors’ reply

We appreciate the interest of Rahman Shah and colleagues in our meta-analysis.1 They argue that the increased stent thrombosis rate recorded in the group of patients assigned to the everolimus-eluting bioresorbable vascular scaffold (BVS) versus everolimus-eluting metallic stent (EES) is related to the lack of routine use of balloon postdilation in the BVS group. There is still no evidence in favour or against this claim, although many experts believe that postdilation helps to improve outcomes after BVS implantation, as advocated in the editorial comment2 Shah and colleagues refer to.